uploads///Saxendra

Novo Nordisk’s Saxendra Could Witness Solid Growth in 2018

By

Nov. 20 2020, Updated 12:18 p.m. ET

Saxendra’s revenue trends

In 4Q17, Novo Nordisk’s (NVO) Saxendra generated revenues of 697 million Danish kroner, which reflected a ~38% YoY (year-over-year) growth in local currency.

In 2017, Saxendra generated revenues of 2.6 billion Danish kroner, which was a ~64% YoY growth in local currency.

In 2017 in the United States, Europe, and AAMEO (Asia, Africa, the Middle East, and Oceania), Saxendra generated revenues of 1.8 billion Danish kroner, 102 million Danish kroner, and 190 million Danish kroner, respectively. In the US market in 2017, Saxendra saw a ~36% YoY growth in local currency.

Article continues below advertisement

Recent developments

Novo Nordisk conducted a Phase 2 clinical trial with the semaglutide injection to evaluate the safety and efficacy of the drug for the treatment of individuals with obesity compared to a placebo and liraglutide. Novo Nordisk presented data at the Endocrine Society’s annual meeting in Chicago

In the Phase 2 clinical trial, after 52 weeks, obese individuals on once-daily semaglutide 0.4 mg (milligrams) subcutaneous injections demonstrated a weight loss up to 13.8% of their total body weight compared to 2.3% loss in body weight for patients receiving the placebo therapy.

In the obesity drugs market, Saxendra’s peers include Orexigen Therapeutics’ (OREXQ) Contrave, Eisai’s Belviq, Vivus’s (VVUS) Qsymia, and GlaxoSmithKline’s (GSK) Alli.

Growth disorder segment revenue trends

In 4Q17, Novo Nordisk’s growth disorder drugs segment generated revenues of 1.7 billion Danish kroner, which was a ~16% YoY decline.

In fiscal 2017, the segment saw a 22% YoY decline in local currencies and generated revenues of 6.7 billion Danish kroner. That included revenues of 2.5 billion Danish kroner, 1.6 billion Danish kroner, 676 billion Danish kroner, 1.6 billion Danish kroner, and 263 million Danish kroner in the United States, Europe, AAMEO, Japan and Korea, and Latin America, respectively.

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.